文献速递临床试验与 GCP

改良潜水口罩(Owner口罩)在COVID-19疫情场景下用于无创通气的有效性:随机临床试验研究方案

Effectiveness of an adapted diving mask (Owner mask) for non-invasive ventilation in the COVID-19 pandemic scenario: study protocol for a randomized clinical trial.
PubMed 文献 · Trials · 2022-03-18

本研究为巴西多中心随机临床试验方案,拟纳入383例呼吸衰竭患者,比较Owner口罩与常规口鼻面罩无创通气的安全性和有效性。主要结局为气管插管率,次要结局包括院内死亡率、PaO2/FiO2比值与PaCO2水平变化、ICU时间、住院时间、不良事件、舒适度与满意度、无创通气成功率及通气变量表现。

要点

  • Owner口罩由潜水口罩改良而成,旨在减少病毒气溶胶传播并保护医护人员。
  • 主要结局为气管插管率,次要结局涵盖 mortality、通气指标、舒适度与满意度等。
  • COVID-19组每组63例,非COVID-19组每组97例,合计383例(含20%失访)。

核心结论

  • 这是COVID-19疫情期间首个关于Owner口罩与常规口鼻面罩安全性和有效性比较的随机对照试验。
  • 实验研究表明Owner口罩能在患者面部实现充分密封,本研究旨在减少病毒在环境中的气溶胶化并提高医护人员安全性。

研究设计与样本

  • 巴西多中心随机临床试验,评估入住重症监护室患者的临床、社会人口学和人体测量学数据。
  • COVID-19伴呼吸衰竭临床体征患者随机分配至Owner口罩无创通气组(n=63)或常规口鼻面罩无创通气组(n=63)。
  • 非COVID-19所致呼吸衰竭患者随机分配至Owner口罩无创通气组(n=97)或常规口鼻面罩无创通气组(n=97)。
  • 总计383例患者,按20%失访率纳入。

关键数值与推荐

  • 主要结局为气管插管率。
  • 次要结局包括院内死亡率、PaO2/FiO2比值与PaCO2水平的差异、重症监护室时间与住院时间、不良效应、口罩使用的舒适度与满意度、无创通气成功率(未进展至气管插管),以及Owner口罩与常规面罩无创通气时通气变量的表现。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Non-invasive ventilation (NIV) is indicated to avoid orotracheal intubation (OTI) to reduce hospital stay and mortality. Patients infected by SARS-CoV2 can progress to respiratory failure (RF); however, in the initial phase, they can be submitted to oxygen therapy and NIV. Such resources can produce aerosol and can cause a high risk of contagion to health professionals. Safe NIV strategies are sought, and therefore, the authors adapted diving masks to be used as NIV masks (called an Owner mask). OBJECTIVE: To assess the Owner mask safety and effectiveness regarding conventional orofacial mask for patients in respiratory failure with and without confirmation or suspicion of COVID-19. METHODS: A Brazilian multicentric study to assess patients admitted to the intensive care unit regarding their clinical, sociodemographic and anthropometric data. The primary outcome will be the rate of tracheal intubation, and secondary outcomes will include in-hospital mortality, the difference in PaO2/FiO2 ratio and PaCO2 levels, time in the intensive care unit and hospitalization time, adverse effects, degree of comfort and level of satisfaction of the mask use, success rate of NIV (not progressing to OTI), and behavior of the ventilatory variables obtained in NIV with an Owner mask and with a conventional face mask. Patients with COVID-19 and clinical signs indicative of RF will be submitted to NIV with an Owner mask [NIV Owner COVID Group (n = 63)] or with a conventional orofacial mask [NIV orofacial COVID Group (n = 63)], and those patients in RF due to causes not related to COVID-19 will be allocated into the NIV Owner Non-COVID Group (n = 97) or to the NIV Orofacial Non-COVID Group (n = 97) in a randomized way, which will total 383 patients, admitting 20% for loss to follow-up. DISCUSSION: This is the first randomized and controlled trial during the COVID-19 pandemic about the safety and effectiveness of the Owner mask compared to the conventional orofacial mask. Experimental studies have shown that the Owner mask enables adequate sealing on the patient's face and the present study is relevant as it aims to minimize the aerosolization of the virus in the environment and improve the safety of health professionals. TRIAL REGISTRATION: Brazilian Registry of Clinical Trials (ReBEC): RBR - 7xmbgsz . Registered on 15 April 2021.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Paiva DN, Wagner LE, Dos Santos Marinho SE, et al. Effectiveness of an adapted diving mask (Owner mask) for non-invasive ventilation in the COVID-19 pandemic scenario: study protocol for a randomized clinical trial. Trials. 2022. PMID: 35303958. doi:10.1186/s13063-022-06133-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。